Proceedings of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30 (Suppl. 2), 2007
For the above-listed supplement, the following duality-of-interest disclosure statements were not included for the participants listed below. The statements shown here were made in the summer of 2005 and refer to relationships held during the previous 12 months. Unless indicated here or in the article itself, participants had no relevant duality of interest to disclose. For the table of contents, please refer to http://care.diabetesjournals.org/content/vol30/Supplement_2.
Thomas A. Buchanan (Diabetes Care 30:S105–S111, S134–S140, S251–S260, 2007) has received grant support from Takeda; has served on an advisory panel for Amylin, Takeda, and Isis; has been a consultant for Amylin, Takeda, Novo Nordisk, Sankyo, SurroMed, PPD, Isis, and Daiichi; and has been a paid speaker for Takeda, Eli Lilly, and GlaxoSmithKline.
Jacob E. Friedman (Diabetes Care 30:S112–S119, 2007) has received research support from Kraft Foods and McNeil Nutritionals and has been a consultant for McNeil Nutritionals.
Alberto de Leiva (Diabetes Care 30:S127–S133, S251–S260, 2007) has received research support from Medtronic, has served on the speakers bureau for Novo Nordisk, and has served on an advisory panel for Bayer.
David. R. Hadden (Diabetes Care 30:S251–S260, 2007) is a consultant for Novo Nordisk, Copenhagen, Denmark.
Lois Jovanovic (Diabetes Care 30:S147–S149, S220–S224, 2007) has received research support from Roche/Densitronic, Medtronic/MiniMed, Eli Lilly and Co., Novo Nordisk, sanofi-aventis, Pfizer, Mannkind, LifeScan, Insulet, Sensys, and Dex Com; served on the speakers bureau for Roche/Densitronic, Medtronic/MiniMed, Eli Lilly, and Novo Nordisk; and served on an advisory panel for Roche/Densitronic, Eli Lilly, Novo Nordisk, sanofi-aventis, Pfizer, Mannkind, LifeScan, Insulet, Sensys, and Dex Com.
David J. Pettitt (Diabetes Care 30:S147–S149, S220–S224, S251–S260, 2007) has received research support from Eli Lilly and Novo Nordisk.
Robert E. Ratner (Diabetes Care 30:S242–S245, 2007) has received research support from Amylin Pharmaceuticals, sanofi-aventis, Eli Lilly, Novo Nordisk, Merck, Pfizer, Proctor & Gamble, AstraZeneca, Takeda, ConjuChem, and GlaxoSmithKline; served on an advisory panel for Amylin Pharmaceuticals, sanofi-aventis, Novo Nordisk, AstraZeneca, Takeda, ConjuChem, and GlaxoSmithKline; and holds stock in Eli Lilly and Merck.
Diane M. Reader (Diabetes Care 30:S188–S193, 2007) has trained industry representatives for Eli Lilly, Novo Nordisk, Aventis, Abbott, and Takeda.
Raitakari OT, Rönnemaa T, Huupponen R, Viikari L, Fan M, Marniemi J, Hutri-Kähönen N, Viikari JS, Lehtimäki T: Variation of the transcription factor 7–like 2 (TCF7L2) gene predicts impaired fasting glucose in healthy young adults: the Cardiovascular Risk in Young Finns Study. Diabetes Care 30:2299–2301, 2007
In the above-listed article, the author name Terho Lehtimäkimd was not spelled correctly. It should have read Terho Lehtimäki. This change has been corrected in the citation above and in the article online.
Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL: Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 30:2321–2326, 2007
In the above-listed article, the scientific units used to describe the MMP-2–to–creatinine ratio should be ng/g creatinine (not pg/g creatinine). This error does not affect the accuracy of the results or the conclusions presented.
